RESUMO
BACKGROUND: Injectable forms of anesthesia for nonsurgical facial rejuvenation, although efficacious, are uncomfortable for the patient. Preclinical studies have demonstrated that laser pretreatment at low energies enhances absorption of topical lidocaine. OBJECTIVES: The authors assess the safety and efficacy of laser-assisted transdermal delivery of topical anesthetic. METHOD: Ten patients were split into 2 groups (A and B). All patients received 15 g of BLT (20% benzocaine, 6% lidocaine, and 4% tetracaine triple anesthetic cream) for 20 minutes with no occlusion. Then the cream was removed and the first blood draw taken. Group A patients were pretreated with the full ablative laser and group B patients with a fractional ablative laser to the full face. A further 15 g BLT was applied for another 20 minutes. Group A patients then underwent full ablative laser treatment, and group B received fractionated ablative laser treatment. Blood draws were taken at 60, 90, 120, 180, and 240 minutes after the initial topical anesthetic application, and the serum was analyzed for lidocaine and monoethylglycinexylidide (MEGX) levels. Patients were asked to rate the pain felt at intervals during the procedure. RESULTS: No patient required supplemental nerve blocks. Pain scores were equivalent at the end of the first pass for both groups (P = .436). Group A patients had significantly lower pain scores at the start of the second laser treatment (P = .045), but pain scores became equivalent by the end (P = .323). Combined serum lidocaine and MEGX levels were significantly higher in group A patients up to 90 minutes (peak average of 0.61 µg/mL for group A and 0.533 µg/mL for group B; P = .0253), which corresponded to greater initial analgesic effect. CONCLUSIONS: Data from this study demonstrate that topical anesthetic for facial rejuvenation can be enhanced with laser pretreatment while maintaining safe blood serum levels. Further studies should examine optimal application amount and time to allow safe multipass facial rejuvenation without the need for invasive nerve blocks.
Assuntos
Analgesia/métodos , Anestésicos Combinados/administração & dosagem , Anestésicos Locais/administração & dosagem , Técnicas Cosméticas , Dor Facial/prevenção & controle , Terapia a Laser , Lidocaína/administração & dosagem , Rejuvenescimento , Envelhecimento da Pele , Administração Cutânea , Analgesia/efeitos adversos , Análise de Variância , Anestésicos Combinados/efeitos adversos , Anestésicos Combinados/sangue , Anestésicos Combinados/farmacocinética , Anestésicos Locais/efeitos adversos , Anestésicos Locais/sangue , Anestésicos Locais/farmacocinética , Benzocaína/administração & dosagem , Biotransformação , Técnicas Cosméticas/efeitos adversos , Técnicas Cosméticas/instrumentação , Desenho de Equipamento , Dor Facial/diagnóstico , Dor Facial/etiologia , Humanos , Terapia a Laser/efeitos adversos , Terapia a Laser/instrumentação , Lasers de Gás , Lasers de Estado Sólido , Lidocaína/efeitos adversos , Lidocaína/análogos & derivados , Lidocaína/sangue , Lidocaína/farmacocinética , Pomadas , Medição da Dor , Absorção Cutânea , Inquéritos e Questionários , Tetracaína/administração & dosagem , Texas , Resultado do TratamentoRESUMO
The purpose of this study was to investigate the effectiveness of a combination of bupivacaine and lidocaine and that of lidocaine alone for local dental anesthesia. First, on different days, healthy volunteers were given 2% lidocaine with 1/80,000 epinephrine or 2% lidocaine with 1/80,000 epinephrine + 0.5% bupivacaine, after which pain was produced with a pulp tester. No difference was found in the time until onset of anesthetic effect between the preparations. However, the duration of anesthetic effect was longer with both lidocaine and bupivacaine than with lidocaine alone. Next, patients undergoing dental surgery were given one of the anesthetic preparations, after which serum concentrations of the anesthetics and epinephrine were measured. The maximal serum concentration of lidocaine was higher and was reached sooner after injection in patients receiving lidocaine alone (1.74 microgram/ml after 5 min) than in patients receiving both anesthetics (0.85 microgram/ml after 3 min). The mean maximal serum concentration of lidocaine was higher in patients receiving lidocaine alone (1.77 +/- 0.03 microgram/ml) than in those receiving both anesthetics (0.99 +/- 0.45 microgram/ml). Furthermore, the mean plasma concentration of epinephrine 1 min after injection was significantly higher in patients receiving lidocaine alone (0.671 ng/ml) than in patients receiving both lidocaine and bupivacaine (0.323 ng/ml). The results of this study suggest that the combination of lidocaine with epinephrine and bupivacaine produces lower systemic levels of the anesthetic and epinephrine and a longer duration of activity than lidocaine with epinephrine alone for local dental anesthesia.
Assuntos
Anestesia Dentária , Anestesia Local , Anestésicos Combinados , Anestésicos Locais , Bupivacaína , Lidocaína , Adolescente , Adulto , Anestésicos Combinados/sangue , Anestésicos Locais/sangue , Bupivacaína/sangue , Epinefrina/sangue , Humanos , Lidocaína/sangue , Fatores de TempoRESUMO
Twenty-five patients undergoing elective cataract day surgery were studied after receiving a dual-injection peribulbar block with a mixture consisting of equal volumes of 2% lignocaine and 0.75% bupivacaine with hyaluronidase. A maximum of 10 ml of solution was used for the initial block; supplementary injections of up to 10 ml were given to five patients. Venous blood was taken prior to the block and then 1, 10, 20, 30, 60 and 90 min after the block. The peak mean concentrations of lignocaine (0.722 microgram.ml-1) and bupivacaine (0.353 microgram.ml-1) were found at 10-20 min after injection when no top-up was given and at 10 min after the top-up injection when required. All measured serum concentrations of lignocaine and bupivacaine were below the accepted toxic levels of the two drugs. However, the highest individual toxicity score after a top-up was 0.915 which was very close to the toxicity threshold (= 1) when a scoring system was used to assess the combined levels.